Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tysabri Or Not Tysabri?

This article was originally published in RPM Report

Executive Summary

FDA is facing one of its toughest decisions on whether to let Biogen Idec/Elan's multiple sclerosis drug Tysabri back on the market. The agency has just begun its re-review of the supplemental BLA and is in the process of determining whether to grant the application expedited priority review.

You may also be interested in...

Safety Panic: Tysabri, Byetta and the Challenge of Risk Communication on Wall Street

There is no question someone is over-reacting to safety issues with Biogen Idec/Elan's Tysabri and Lilly/Amylin's Byetta. But is it FDA-or investors?

Celgene's Revlimid Serves as Precedent for Tysabri Delay Concerns

FDA says it needs more time to review an application for the MS drug Tysabri for treatment of Crohn's Disease. Investors worry the delay may be a red flag of safety issues related to the new indication. Recent history with more complex risk plans indicates Wall Street may be getting worked up over nothing.

The Risk of Risk Management

Risk management plans are an increasingly common feature of new drug approvals, and Congress seems set on making them a standard part of the FDA review process. Industry seems willing to go along, accepting some more restricitions on new products in exchange for restoring confidence in drug safety. There is only one problem: FDA is not so sure this is a great idea.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts